Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25675527 | 0.88 | USP30 (0.58) | USP30HDAC6HDAC4HDAC1RIPK1 | |
| SCHEMBL30370293 | 0.88 | HDAC1 (0.54) | USP30HDAC6HDAC1RIPK1 | |
| SCHEMBL24073261 | 0.84 | HDAC1 (0.49) | USP30HDAC6HDAC1 | |
| SCHEMBL30370264 | 0.84 | HDAC1 (0.49) | USP30HDAC6HDAC1 | |
| SCHEMBL25676690 | 0.81 | USP30 (0.54) | USP30HDAC6HDAC1 | |
| SCHEMBL31017667 | 0.81 | USP30 (0.54) | USP30HDAC6HDAC1 | |
| SCHEMBL30474057 | 0.81 | HDAC1 (0.47) | USP30HDAC6HDAC1RIPK1 | |
| SCHEMBL24072831 | 0.81 | HDAC1 (0.47) | USP30HDAC6HDAC1RIPK1 | |
| SCHEMBL24073669 | 0.81 | HDAC1 (0.47) | USP30HDAC6HDAC1RIPK1 | |
| SCHEMBL24073645 | 0.80 | HDAC1 (0.47) | USP30HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | disclosed |